The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated...
Date First Received: August 22, 2006
Last Updated: June 10, 2008
Verified by: University of Connecticut, June 2008
Clinical Trial Phase: Phase 4 | Start Date: February 2004
Overall Status: Recruiting
Estimated Enrollment: 160
Brief Summary
Official Title: “Sertraline Pharmacotherapy for Alcoholism Subtypes”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated.
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: March 2009
Detailed Clinical Trial Description
In an effort to broaden the options for pharmacotherapy of alcoholism, this study will examine the effects of sertraline, a selective serotonin reuptake inhibitor (SSRI), for the treatment of alcohol dependence. The study is based on evidence that, although SSRI therapy is not appropriate for all alcoholics, there exists a substantial subgroup of alcoholics for whom SSRI's appear to exert a clinically important effect. Sertraline is among the most widely prescribed psychotropic medications in the world. Consequently, this study will examine the safety and efficacy of sertraline, the mechanism and duration of those effects and the best method for subtyping alcoholics to identify individuals for whom the medication is most likely to produce a clinically important reduction in drinking behavior.
The study employs a stratified, parallel groups, prospective design in which patient subtype (early-onset/late-onset) is used to assign subjects randomly to medication group in a placebo-controlled trial of sertraline. The study will include a 14-week treatment period, during which 160 early-onset or late-onset alcoholics will receive either sertraline (to a maximum of 200 mg/day) or matching placebo. Daily process measures of positive and negative events, global perceived stress, mood, desire to drink, and drinking frequency and intensity, collected using interactive voice response technology, will provide insight into the mechanisms by which sertraline may exert its effects. Coping-skills training will be provided weekly for the first 6 weeks, then every other week for the last 8 weeks of the study. A 6-month post-treatment follow-up period will evaluate the duration of medication effects.
This study will also examine the relation between genotypes at a number of relevant loci and both risk of alcohol dependence and response to sertraline treatment.
Intervention(s) in this Clinical Trial
- Drug: sertraline
- sertraline (to a maximum of 200 mg/day) for 14-week treatment period
- Drug: Placebo
- placebo for 14-week treatment period
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- sertraline
- Placebo Comparator: 2
- Placebo
Outcome Measures for this Clinical Trial
Primary Measures
- Number of days on which subjects drink
- Time Frame: 14-week treatment period, 6 months follow up
Safety Issue?: No
- Time Frame: 14-week treatment period, 6 months follow up
Secondary Measures
- Likelihood of total abstinence during the treatment period
- Time Frame: 14-week treatment period, 6 months follow up
Safety Issue?: No
- Time Frame: 14-week treatment period, 6 months follow up
- Mean daily alcohol consumption
- Time Frame: 14-week treatment period, 6 months follow up
Safety Issue?: No
- Time Frame: 14-week treatment period, 6 months follow up
- Number of days of heavy drinking (defined as >= 4 drinks for females and >= 5 drinks for males)
- Time Frame: 14-week treatment period; 6 months follow up
Safety Issue?: No
- Time Frame: 14-week treatment period; 6 months follow up
- Carbohydrate-deficient transferrin levels
- Time Frame: 14-week treatment period; 6 months follow up
Safety Issue?: No
- Time Frame: 14-week treatment period; 6 months follow up
- Level of alcohol-related problems
- Time Frame: 14-week treatment period; 6 months follow up
Safety Issue?: No
- Time Frame: 14-week treatment period; 6 months follow up
- Frequency of serious adverse events
- Time Frame: 14-week treatment period; 6 months follow up
Safety Issue?: Yes
- Time Frame: 14-week treatment period; 6 months follow up
- Frequency of moderate or severe adverse events
- Time Frame: 14-week treatment period; 6 months follow up
Safety Issue?: Yes
- Time Frame: 14-week treatment period; 6 months follow up
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Current episode (i.e., in the preceding month) of alcohol dependence defined by Diagnostic and Statistical Manual of Mental Disorders 4th ed (DSM-IV) criteria
- 18-65 years of age
- Abstinent from alcohol for a period of at least 3 days prior to baseline research assessment
- Able to read English and complete study evaluations
- Male, or if female, without active reproductive potential
- Participants will have signed informed consent
Exclusion Criteria:
- Currently meets criteria for dependence on a psychoactive substance other than alcohol and nicotine
- Regular use of psychoactive drugs including anxiolytics and antidepressants.
- Current use of disulfiram or naltrexone
- Current major depression or psychosis (or other severe psychiatric disability e.g., suicidality, current mania)
- Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid, or cardiac pathology, which in the opinion of the evaluating physician would preclude the patient from study adherence or be of potential harm to the subject
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: University of Connecticut
Overall Clinical Trial Officials and Contacts
Henry R. Kranzler, MD Principal Investigator University of Connecticut Health Center
Overall Contact: Kristen A. Tremblay, MPH 860-679-4755 tremblay@psychiatry.uchc.edu
Additional Information
Information obtained from ClinicalTrials.gov on September 04, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00368550
Study ID Number: 03-225-2
ClinicalTrials.gov Identifier: NCT00368550
Health Authority: United States: Federal Government
University of Connecticut Health Center, Dept. of Psychiatry Research Studies
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.